PCRX Pacira BioSciences
- 27.210
- -0.110-0.40%
- 27.657
- +0.447+1.64%
Pacira BioSciences News
Investors Still Waiting For A Pull Back In Pacira BioSciences, Inc. (NASDAQ:PCRX)
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may consider Pacira BioSciences, Inc. (NASDAQ:PCRX) as a stock to avoid entirely with it
Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
PDF Version TAMPA, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results after the close of the U
These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Reasonably Well
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts
Across the recent three months, 6 analysts have shared their insights on Pacira BioSciences (NASDAQ:PCRX), expressing a variety of opinions spanning from bullish to bearish.The table below provides a
Express News | Needham Reiterates Buy on Pacira BioSciences, Maintains $45 Price Target
Aggressive Stock Portfolio: 13 Stocks Picked by Analysts
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
PDF Version TAMPA, Fla., April 02, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 23rd Annual Nee
Pacira BioSciences Independent Director Gary Pace Sells 85% Of Holding
We wouldn't blame Pacira BioSciences, Inc. (NASDAQ:PCRX) shareholders if they were a little worried about the fact that Gary Pace, the Independent Director recently netted about US$3.7m selling shares
Express News | Pacira Biosciences Announced That FDA Has Granted Regenerative Medicine Advanced Therapy Designation To Pcrx-201 (Enekinragene Inzadenovec), Gene Therapy Product For Knee Osteoarthritis
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
PDF Version -- PCRX-201 is the first gene therapy product candidate to receive RMAT designation for osteoarthritis ---- Designation supported by encouraging preliminary data from 72-patient Phase 1
Director Gary Pace Sells 119,323 Shares of Pacira BioSciences Inc (PCRX)
Pacira BioSciences(PCRX.US) Director Sells US$3.66 Million in Common Stocks
$Pacira BioSciences(PCRX.US)$ Director PACE GARY W sold 119.32K shares of Common Stocks on Mar 6, 7, 8, 2024 at an average price of $30.64 for a total value of $3.66 million.Source: Announcement What
Pacira Biosciences Insider Sold Shares Worth $3,656,226, According to a Recent SEC Filing
Gary W Pace, Director, on March 06, 2024, sold 119,323 shares in Pacira Biosciences (PCRX) for $3,656,226. Following the Form 4 filing with the SEC, Pace has control over a total of 22,127 shares of t
Teva Upgraded at J.P. Morgan on Upcoming Catalysts
Pacira BioSciences Coverage Assumed by JP Morgan at Overweight
Pacira BioSciences Coverage Assumed by JP Morgan at Overweight
Express News | JP Morgan Assumes Pacira BioSciences at Overweight, Announces Price Target of $45
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
PDF Version TAMPA, Fla., March 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays 26th A
11 Best Small Cap Pharma Stocks to Invest In
Express News | HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $57 Price Target
Pacira BioSciences Is Maintained at Outperform by RBC Capital
Pacira BioSciences Is Maintained at Outperform by RBC Capital
Analysis
Price Target
No Data
